Recent advances in engineered nanozymes for precision lung cancer therapy.

Fushuang Zheng, Hongyan Zhang, Feng Guo, Xiajie Wu, Kuanbing Chen, Nana Li, Hengyi Yan

Abstract readReview

In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fushuang ZhengShengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.

Hongyan ZhangShengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.

Feng GuoShengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.

Xiajie WuShengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.

Kuanbing ChenShengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.

Nana LiDepartment of Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.

Hengyi YanShengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer therapy remains constrained by adaptive resistance and the inability of current modalities to effectively reprogram the tumor microenvironment (TME). Nanozymes introduce a catalytic paradigm that converts intrinsic TME features into therapeutic leverage. Here, we frame nanozymes not merely as drug carriers but as active regulators of tumor biology, capable of rewiring redox homeostasis, disrupting metabolic dependencies, and amplifying antitumor immunity. Through catalytic generation of reactive species, oxygen modulation, and cascade reactions, nanozymes sensitize tumors to chemo-, radio-, and photo-based therapies while promoting immunogenic cell death. This review further highlight design logic centered on catalytic programmability and spatiotemporal activation, and discuss the key barriers to clinical translation, defining a roadmap toward next-generation catalytic nanomedicine.

Indexed as

BiomaterialsDrug deliveryLung cancerNanozymesTarget therapy

Identifiers

PMID42376249

DOI10.1016/j.mtbio.2026.103366

PMCPMC13312534

What Socratic holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.